Aethlon Medical – Consensus Indicates Potential 157.4% Upside

Broker Ratings

Aethlon Medical found using ticker (AEMD) now have 2 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 8 and 6 and has a mean target at 7. Now with the previous closing price of 2.72 this indicates there is a potential upside of 157.4%. The 50 day MA is 2.08 and the 200 day MA is 1.74. The company has a market cap of $30m. You can visit the company’s website by visiting:

Aethlon Medical, a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical has a collaboration with the University of Pittsburgh for studies related to head and neck cancer. The company is based in San Diego, California.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on whatsapp

AIM All Share Index